Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Behiye Kodal"'
Autor:
Jeffrey S Miller, Bahram Valamehr, Behiye Kodal, Martin Felices, Peter Hinderlie, Laura Bendzick, Carly Selleck, Philippa R Kennedy, Quinlan M Kile, Rhett L Waller, Marissa Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/bf97dbd4ffa1495e96559f1f0de00ba8
Publikováno v:
Immuno, Vol 3, Iss 2, Pp 237-249 (2023)
Chemotherapy-refractive multiple myeloma (MM) is serious and life-threatening, and better treatments are urgently needed. BCMA is a prominent marker on the cell surface of MM cells, rendering it an accepted target for antibody therapy. Considering th
Externí odkaz:
https://doaj.org/article/3e58da5685194a748d30a8678bd5e8c9
Autor:
Philippa R. Kennedy, Daniel A. Vallera, Brianna Ettestad, Caroline Hallstrom, Behiye Kodal, Deborah A. Todhunter, Laura Bendzick, Peter Hinderlie, Joshua T. Walker, Brittany Pulkrabek, Ira Pastan, Robert A. Kratzke, Naomi Fujioka, Jeffrey S. Miller, Martin Felices
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC) that shows promise as an immunotherapeutic target in phase I clinical trials. However, the i
Externí odkaz:
https://doaj.org/article/cf1f398a8d974c5e8e36f681326c38aa
Autor:
Jeffrey S Miller, Behiye Kodal, Martin Felices, Peter Hinderlie, Michael F Kaminski, Laura Bendzick, Rachel Hopps, Marissa Kauffman, Yvette Soignier, Joshua T Walker, Todd R Lenvik, Melissa A Geller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background The tumor microenvironment contains stromal cells, including endothelial cells and fibroblasts, that aid tumor growth and impair immune cell function. Many solid tumors remain difficult to cure because of tumor-promoting stromal cells, but
Externí odkaz:
https://doaj.org/article/493a148c4e544ff7b54acc09de5b0af3
Autor:
Joshua Walker, Nicholas Zorko, Behiye Kodal, Alexander Lenvik, Todd Lenvik, Daniel Vallera, Alejandro Garcia, Martin Felices
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/51f8f192256a47a3a73266200f93f317
Autor:
Daniel A. Vallera, Felix Oh, Behiye Kodal, Peter Hinderlie, Melissa A. Geller, Jeffrey S. Miller, Martin Felices
Publikováno v:
Cancers, Vol 13, Iss 16, p 3994 (2021)
Clinical studies validated antibodies directed against HER2, trastuzumab, and pertuzumab, as useful methodology to target breast cancer cases where HER2 is expressed. The hope was that HER2 targeting using these antibodies in ovarian cancer patients
Externí odkaz:
https://doaj.org/article/8b95513dab3844e0b8a382fef0abdb4d
Autor:
Daniel A. Vallera, Soldano Ferrone, Behiye Kodal, Peter Hinderlie, Laura Bendzick, Brianna Ettestad, Caroline Hallstrom, Nicholas A. Zorko, Arpit Rao, Naomi Fujioka, Charles J. Ryan, Melissa A. Geller, Jeffrey S. Miller, Martin Felices
Publikováno v:
Cancers, Vol 12, Iss 9, p 2659 (2020)
We improved the bispecific antibody platform that primarily engages natural killer (NK) cells to kill cancer cells through antibody-dependent cellular cytotoxicity (ADCC) by adding IL-15 as a crosslinker that expands and self-sustains the effector NK
Externí odkaz:
https://doaj.org/article/e5b5e5dd048c4eeab22547eee35c74ef
Autor:
Martin Felices, Erin Wesley, Laura E. Bendzick, Behiye Kodal, Rachel Hopps, Bartosz Grzywacz, Peter Hinderlie, Jeffrey S. Miller, Melissa A. Geller
Publikováno v:
Cancer Immunology Research. 11:674-686
Immune checkpoint blockade (ICB) has changed the standard of care for many patients with cancer, yet no ICB is approved for ovarian cancer. We hypothesized that maintenance therapy with an IL15 “superagonist” (N-803) and ICB in combination could
Autor:
Frank Cichocki, Jodie P. Goodridge, Ryan Bjordahl, Sajid Mahmood, Zachary B. Davis, Svetlana Gaidarova, Ramzey Abujarour, Brian Groff, Alec Witty, Hongbo Wang, Katie Tuininga, Behiye Kodal, Martin Felices, Greg Bonello, Janel Huffman, Thomas Dailey, Tom T. Lee, Bruce Walcheck, Bahram Valamehr, Jeffrey S. Miller
Publikováno v:
Blood. 140:2451-2462
Substantial numbers of B cell leukemia and lymphoma patients relapse due to antigen loss or heterogeneity after anti-CD19 chimeric antigen receptor (CAR) T cell therapy. To overcome antigen escape and address antigen heterogeneity, we engineered indu
Publikováno v:
Immuno; Volume 3; Issue 2; Pages: 237-249
Chemotherapy-refractive multiple myeloma (MM) is serious and life-threatening, and better treatments are urgently needed. BCMA is a prominent marker on the cell surface of MM cells, rendering it an accepted target for antibody therapy. Considering th